Fig. 7

Realignment of intracellular NADPH distribution through isocitrate/α-ketoglutarate (α-KG) shuttle compromises OxPhos activity. a Schematic of isocitrate/α-KG shuttle machinery in connecting cytosolic and mitochondrial NADPH pool. b Immunoblot analysis of SLC25A1 expression in negative control (NC) or Slc25a1 siRNA transfected ECs following vehicle, TGF-β1 or SAC treatment. α-Tubulin was used as the loading control (n = 3). c Relative NADPH abundance in whole-cell and mitochondrial fractions in NC siRNA or Slc25a1 siRNA transfected ECs post vehicle or TGF-β1 treatment (n = 3). d Fluorescent staining of TMRE in NC siRNA or Slc25a1 siRNA transfected ECs post vehicle or TGF-β1 treatment, scale bar, 20 μm (n = 3). e, f Relative complex I and complex II activity in NC siRNA or Slc25a1 siRNA transfected ECs post vehicle or TGF-β1 treatment (n = 3). g Relative NADPH abundance in whole-cell and mitochondrial fractions in quiescent, transformed, and 1, 2, 3-benzenetricarboxylic acid hydrate (BTA)-treated ECs (n = 3). h Fluorescent staining of TMRE in quiescent, transformed, and BTA-treated ECs, scale bar, 20 μm (n = 3). i, j Relative complex I and complex II enzymatic activity in quiescent, transformed, and BTA-treated ECs (n = 3). Data are represented as mean ± SD. ^##p < 0.01, ^###p < 0.001 versus control group. *p < 0.05, **p < 0.01, ***p < 0.001, N.S., nonsignificant versus model group (g, i, j) or indicated group